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ABSTRACT
Background. Carbapenem-resistant Enterobacteriaceae, including Escherichia coli and
Klebsiella pneumoniae, are newly emerging pathogens of public health importance. Currently no
nationally representative or mandatory surveillance or reporting system exists to examine trends
of these important pathogens.
Objective. The purpose of the current study was to estimate trends in overall microbial burden
and carbapenem resistance in E. coli and K. pneumoniae and to understand the extent to which
hospitals which report to voluntary surveillance systems represent all hospitals in the United
States.
Design. We conducted a descriptive study to compare the hospitals participating in voluntary
reporting systems of the University HealthSystem Consortium and the National Healthcare
Safety Network with the Healthcare Utilization Project’s Nationwide Inpatient Sample, a
nationally representative sample of hospital discharges.
Methods. Descriptive analyses examined hospital characteristics (region, bed size, hospital
control, teaching status, case mix index) and patient characteristics (age, sex, race/ethnicity,
admission source, admission type, discharge status, primary payer) of participant hospitals versus
all US hospitals. ICD-9-CM codes identified discharges coded for E. coli and K. pneumoniae
diagnoses; linear regression was used to evaluate trends in overall microbial burden of E. coli
and K. pneumoniae in all US Hospitals and US Academic Centers. Trends in E. coli and K.
pneumoniae resistance to carbapenem were also evaluated in hospitals participating in voluntary
surveillance systems (n=13).
Results. Between 2002 and 2007, slight increasing trends in burden of both E. coli and K.
pneumoniae were observed (E. coli: slope = 0.0537; K. pneumoniae slope = 0.0168). Hospitals
participating in voluntary surveillance systems are larger and care for fewer elderly patients than
all US hospitals.
Conclusions. These results suggest that hospitals that participate in voluntary surveillance
systems like the National Healthcare Safety Network and the University HealthSystem
Consortium may underrepresent trends in smaller hospitals, as well as those that treat elderly
patients. Increasing overall burden of infection due to these isolates only reinforces the
importance carbapenem resistance in E. coli and K. pneumoniae. This important public health
threat may warrant the creation of a national, mandatory reporting system for these and other
antimicrobial resistant organisms.
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INTRODUCTION
Antimicrobial resistance, especially in heath care settings, has emerged as a significant
public health threat.1 As multidrug resistant organisms have increased, so has use of broad
spectrum agents to treat them.1 With their broad spectrum activity for gram positives, gram
negatives and anaerobic bacteria,2 carbapenems are frequently used as a last line of therapy.3,4
Newer antimicrobial resistant species such as Carbapenem-resistant Enterobacteriaceae
(CRE), including Escherichia coli and Klebsiella pneumoniae are beginning to emerge.
Enterobacteriaceae are gram-negative bacteria which are part of the normal human intestinal
flora and are frequently spread via fecal-oral contamination.1 Pathogenic isolates can be carried
in the gut for years in healthy adults and only emerge when intestinal conditions change.1
The first carbapenem resistance was seen in K. pneumoniae in 2000 in a hospital in New
York city;5 the first carbapenem hydrolyzing enzymes in E. coli isolates were found in 2005.6
Most alarming was the discovery of a community-associated isolate of carbapenem-resistant E.
coli in Greece in 2009.7 CRE was originally identified in the Northeast United States,5 but are
now beginning to spread in the United States and Europe.8
The emergence of CRE is a great public health concern because there is no reliable
treatment. CRE are typically resistant not only to carbapenems, but also to polymixin B sulfate
and third generation cephalosporins.5 In addition, many carbapenem resistant isolates of K.
pneumoniae also possess extended spectrum beta-lactamases,5 and genes conferring resistance
may be accompanied by virulence factors.1 In many cases, in vitro analysis has shown some
isolates to be susceptible to tigecycline, gentamicin, and colistin.5,9-11 Clinical treatment
successes have resulted from combinations of gentamicin and colistin12 or tigecycline and
colistin.13 In a case control study, removal of infection site was also part of a successful
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treatment strategy.14 With few novel treatment options in development, treatment of CRE
infections remains challenging.
Despite the severity of the emerging CRE and other multi-drug resistant organisms, the
US currently has only voluntary antimicrobial resistance surveillance systems. Due to their low
incidence in any single institution, it is likely that current, voluntary public health surveillance
systems underrepresent the spread of these organisms.1 One surveillance system currently in use
is the National Healthcare Safety Network. Designed to be a national surveillance system for
both patient and healthcare personnel safety, it began collecting data from participant hospitals in
2005.15 Another example is the University HealthSystem Consortium which, represents
approximately 90% of the United States’ non-profit academic medical centers,16 and through
collaboration among participant hospitals, has provided a limited mechanism of surveillance of
data from its member organizations since 2002. No single mandatory reporting system exists to
track the emergence and increase of these dangerous pathogens. The purpose of this study was
twofold. First, we estimated trends in both overall microbial burden and carbapenem resistance
in E. coli and K. pneumoniae. Second, we sought to understand the extent to which hospitals
pzrticipating in voluntary surveillance systems represent all hospitals in the United States.

METHODS
We conducted a descriptive study to evaluate the extent to which voluntary public health
reporting surveillance systems of carbapenem-resistant Enterobacteriaceae (CRE) may
adequately represent all hospitals in the US. This study was not funded and the authors have no
conflicts of interest to disclose.
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Data Sources
Between September 2009 and January 2010, we thoroughly investigated multi-site data
sources of antimicrobial resistance and identified two: the National Healthcare Safety Network
(NHSN) and the University HealthSystem Consortium (UHC). We also identified two data
sources which provide nationally representative hospital estimates: the National Hospital
Discharge Survey and the Healthcare Utilization Project Nationwide Inpatient Sample (HCUPNIS). While the latter data sources both enable nationally representative estimates of hospital
discharges, we selected the HCUP-NIS for three reasons. First, its larger sample size and greater
number of available diagnosis codes enabled estimation of rare events (such as CRE) with
greater precision. Second, this source provided a more extensive array of data elements
important for this research. Third, the HCUP-NIS provided data specifically on hospital
characteristics, which allowed stratification by teaching status. Each data source used in final
analysis is discussed in detail below.
The University HealthSystem Consortium (UHC)
The University HealthSystem Consortium (UHC) is composed of 107 participant
academic medical centers and 233 of their associated hospitals, representing approximately 90%
of the United States’ non-profit academic medical centers.16 The UHC provides a mechanism for
collaboration for research across academic medical centers, which are geographically distributed
throughout the US.16 Approximately 75 academic medical centers participating in the UHC
Clinical Database/Resource Manager module were approached by investigators at VCU for
participation in surveillance of microbial-resistance rates. Investigators requested antibiograms
from each hospital for each year from 2002 to 2008. Hospitals were provided with a $100
incentive per year for sharing their data. Isolates were categorized as either susceptible or
resistant; each hospital used their own standards to measure antimicrobial sensitivity (not
reported). Hospitals were considered “UHC Participant Hospitals” and included in descriptive
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distribution analysis if they contributed antibiogram data for at least one year in the study period
(2002-2008, n=42). Hospitals were included in descriptive trend analysis only if data were
available for all years in the study period (2002-2008, n = 13).
National Healthcare Safety Network (NHSN)
Data from the National Healthcare Safety Network (NHSN) are not available publicly.
While we were unable to secure data from the NHSN, we were able to extract data from a
published report based on the NHSN.15 The NHSN was implemented in 2005, integrating three
former systems: the National Nosocomial Infections Surveillance (NNIS) system, the Dialysis
Surveillance Network and the National Surveillance System for Healthcare Workers. Managed
by the Centers for Disease Control and Prevention Division of Healthcare Quality Promotion, the
NHSN compiles monthly electronically reported surveillance data on healthcare associated
infections in approximately 460 participant healthcare facilities.15
Healthcare Cost and Utilization Project- Nationwide Inpatient Sample (HCUP-NIS)
The Nationwide Inpatient Sample (NIS) is part of the Healthcare Cost and Utilization
Project (HCUP) sponsored by the Agency for Healthcare Research and Quality. HCUP-NIS data
are collected to track and analyze national trends in health care utilization, access, charges,
quality and outcomes.17
The HCUP-NIS uses about 1,000 hospitals to draw a nationally representative, complex
sample of US non-federal, short-term, general, specialty and non-institutional community
hospitals. From each sampled hospital, all discharges for the sample year are included, totaling 5
to 9 million annual discharges, enabling analyses of rare conditions such as E. coli and K.
pneumoniae. Available data contain both hospital and patients characteristics; the number of
included diagnosis codes per discharge varies over time and by state.17,18
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ANALYSIS
Evaluation of the National Burden of Total Escherichia coli and Klebsiella pneumoniae
Diagnoses
We evaluated trends in the national burden of Escherichia coli and Klebsiella
pneumoniae infections from all US Hospitals and US Academic Centers. Hospital discharge data
from the HCUP-NIS were used to measure the total national burden of E. coli and K.
pneumoniae diagnoses (regardless of antibiotic susceptibility). As the number of ICD-9-CM
codes captured in the HCUP-NIS varies over time and by state, up to 15 International
Classification of Disease (ICD)-9-CM codes were captured for each discharge record. All
infection diagnosis codes of either infection (E. coli: 008.0, 008.00, 008.01, 008.02, 008.03,
008.04, 008.09, 038.42, 041.4, 482.82; K. pneumoniae: 482.0, 041.3) were aggregated separately
by year. Thus for each year, the proportion of hospital discharges with a diagnosis of E. coli or
K. pneumoniae was calculated for 2002-2007, the most recently available data.
From these aggregated data, we developed two linear regression models; one using the
dependent variable for presence of any ICD-9-CM code for E. coli, and one for K. pneumoniae.
Each model included a single determinant- year. We interpreted the beta coefficient for the
determinant as the change in proportion of diagnoses of E. coli (or K. pneumoniae) per one unit
increase in year.
Carbapenem Resistance Trends among Select UHC Participant Hospitals
Using antibiogram data available from the UHC Participant Hospitals, we conducted a
descriptive evaluation of CRE resistance trends. Aggregate incident annual sensitivity data on
carbapenem resistant isolates of Klebsiella pneumoniae and Escherichia coli were extracted from
available antibiograms for analysis. Carbapenem resistance was normalized per 1,000 discharges
annually for each species. As there were only 13 hospitals contributing data for all years, no
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statistical tests were completed; data were plotted to visually inspect for descriptive trends in
resistance.
Comparison of Patient and Hospital Characteristics
To assess the extent to which hospitals participating in non-mandatory surveillance of
CRE are similar to all hospitals nationwide, and whether discharges from these participant
hospitals are similar to those from hospitals nationwide, we first examined which conceptual
domains were available for analysis across both HCUP-NIS and UHC data sources. Once
identified, we compared aggregated discharge-level and hospital-level characteristics. To better
approximate the population of academic medical centers from which UHC hospitals are selected,
stratified analysis using hospitals from the HCUP-NIS was completed using two samples: 1) All
US Hospitals: All hospitals sampled by the HCUP-NIS and 2) US Academic Centers: HCUPNIS Academic Medical Centers, limited to self-identified teaching hospitals.
The comparisons of interest were 1) all US Hospitals versus UHC Participant Hospitals;
and 2) US Academic Centers versus UHC Participant Hospitals. For analysis of HCUP-NIS
data, we weighted for complex survey design using appropriate SAS survey procedures. P-values
based on large samples such as this one are rarely of use because unimportant differences will be
statistically significant.19 Therefore, we a priori used an absolute difference of 5% in
distributions to indicate evidence of meaningful differences.
Discharge-level characteristics included: patient age group (younger than 18; 18-30
years; 31-50 years; 51-64 years; 65 and older), gender, race/ethnicity, (White; Black/African
American; Hispanic/Latino; Asian/Pacific Islander; American Indian/Alaskan Native), admission
source (emergency room; another hospital; another facility; court/law enforcement; routine, birth
or other), admission type (emergency; urgent care; elective; newborn; trauma center), discharge
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status (died or did not die during hospitalization), and primary payer source (Medicare;
Medicaid; private insurance or HMO; self pay; no charge for provided service; other).
Hospital-level variables included: geographic region, teaching status, bed size, hospital
control, and mean case mix index. Region was defined using four regions (Northeast, Midwest,
South, West), as characterized by the US Census Bureau. Hospital teaching status was selfdesignated by each facility as teaching or non-teaching. For HCUP-NIS data, bed size was
categorized as “small” “medium” or “large”, and was based on the number of hospital beds
specific to the individual hospital’s region, location and teaching status, as described
previously.17 To approximate this distribution, UHC hospital bed sizes were divided similarly to
teaching centers captured by the HCUP-NIS: small, (< 250 beds) medium (250-399 beds) and
large (> 400 beds). NHSN bed size analysis was extracted from an available report15 and was
categorized as small, (< 200 beds) medium, (200 - 499 beds) and large (> 500 beds).
For the HCUP-NIS, when the sample size of hospitals was sufficiently large, hospital
control was stratified as “public”, “non-profit”, and “proprietary.” For smaller strata,
stratification was simply “public” and “private, collapsed.” For all other strata, no stratification
was done due to small sample size, all hospitals were categorized as “collapsed, no control
stratification done,” as described previously.20
Hospital case mix index (CMI) was calculated using diagnosis related group (DRG)
relative weights downloaded from the Centers for Medicare and Medicaid Services.21 DRG
weights were applied to each discharge based on reported DRG and then hospital CMI was
calculated as described previously.22 CMI for each hospital from the HCUP-NIS were averaged,
resulting in a mean CMI across all US Hospitals and US Academic Centers (assessed
separately). For UHC Participant Hospitals, CMI was provided for each hospital, and a mean
CMI measure was calculated.
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RESULTS
Evaluation of the National Burden of Escherichia coli and Klebsiella pneumoniae
Figure 1 shows the proportion of hospital discharges with a diagnosis of E. coli (Panel A)
and K. pneumoniae (Panel B) for all US Hospitals and US Academic Centers. Between 2002 and
2007, increases in the proportion of discharges for both E. coli and K. pneumoniae were
observed. In 2007, an estimated 149,767 hospital discharges included codes for E. coli and
562,809 for K. pneumoniae (among all US Hospitals). In both cases, higher E. coli and K.
pneumoniae diagnosis rates were seen at US Academic Centers than at all US Hospitals. For all
discharges from US Hospitals with a diagnosis of E. coli or K. pneumoniae, evidence of slight
positive linear trends were shown for both species (E. coli: slope = 0.0537, Std. Err. = 0.00547;
K. pneumoniae slope = 0.0168, Std. Err. = 0.00197). For discharges from US Academic Centers,
evidence of positive linear trends were also shown for both species (E. coli: slope =0.0489, Std.
Err. = 0.00580; K. pneumoniae slope = 0.01993, Std. Err. = 0.00113).
CRE Antibiogram Trends among UHC Participant Hospitals
Figure 2 shows the trends in aggregate carbapenem resistance of Klebsiella pneumoniae
and Escherichia coli. For carbapenem resistance in E. coli, no clear directional trend was seen,
other than a nominal decrease in resistance in 2005. Hospital-level resistance rates in this species
seem to be stable for the years evaluated. For K. pneumoniae, the data point toward evidence of a
slight decrease in resistance until 2005, at which point an increasing trend begins to emerge.
Current rates are nominally higher than those found earlier in this decade (data not shown).
Comparison of Patient Characteristics
Table 1 shows the comparison of discharges from hospitals which participate in voluntary
surveillance systems of CRE to discharges from all US hospitals, as well as all US Academic
Centers. Overall, characteristic distributions of discharges from UHC Participant Hospitals
approximated all US Academic Hospitals. There were meaningful differences between hospitals
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voluntarily reporting CRE surveillance data and all US hospitals with respect to patient age,
race/ethnicity, admission source and primary payer source.
More discharges from all US hospitals were from patients 65 or older (US Hospitals:
33.5%, US Academic Centers: 29.1% and UHC Participants: 24.3%) and had Medicare as their
primary payer source (US Hospitals: 36.4%, US Academic Centers: 31.9%, and UHC
Participants: 29.5%). With respect to reported race/ethnicity, discharges from all US Hospitals
were more frequently White (US Hospitals: 67%, US Academic Centers: 59.6% and UHC
Participants: 60.7%), while discharges from UHC Participant Hospitals were more frequently
Black/African American (US Hospitals: 15%, US Academic Centers: 19.2%, UHC Participants:
24.7%).
Differences were also observed for admission source: discharges from all US Hospitals
were more likely admitted from the emergency room, (US Hospitals: 44.5%, US Academic
Centers: 42.8%, and UHC Participants: 39.4%) while those from UHC Participant Hospitals
were more likely admitted from another hospital (US Hospitals: 3.3%, US Academic Centers:
4.6%, UHC Participants: 7.9%).
Comparison of Hospital Characteristics
Table 2 shows the comparisons of hospital characteristics: hospitals who voluntarily
report CRE surveillance rates to all US Hospitals and US Academic Centers. UHC Participant
Hospitals were better approximated by US Academic Centers than by all US Hospitals. Relative
to all US hospitals, the UHC Participant Hospitals overrepresented the Northeast,
underrepresented the Midwest and Southwest. UHC Participant Hospitals underrepresented small
hospitals overall, as well as small academic hospitals (US hospitals: 45.2%, US Academic
Centers: 28.0%, UHC Participants: 4.8%). When comparing UHC Participant Hospitals to
NHSN Participant Hospitals, UHC Hospitals were more likely to be large (UHC: 73.8%, NHSN:
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20.5%). All UHC Participants Hospitals were non-profit teaching centers. While only 18.2% of
all US Hospitals are teaching centers, because of UHC’s deliberate sampling on academic
medical centers, 100% of their hospitals are teaching centers. UHC Participant Hospitals also
had a higher mean case mix index (CMI = 1.64, Std. Dev. = 0.18) compared to all US Hospitals
(CMI = 1.18, Std. Dev. = 0.0005) and US Academic Centers (CMI = 1.25, Std. Dev. = 0.0009).

DISCUSSION
Overall, we observed slight increased trends in hospital discharges coded E. coli and K.
pneumoniae diagnoses. No distinct trend in carbapenem resistance in E. coli was observed in the
13 hospitals with consistent contributions to the voluntary reporting system, but suggestions of
an increase in carbapenem resistance in K. pneumoniae since 2005 is apparent. We found that
hospitals participating in volunteer CRE surveillance systems may not adequately represent all
US hospitals. Hospitals participating in voluntary reporting systems underrepresent hospitals in
the South and Midwest US. Further, the hospitals voluntarily reporting are likely not capturing
trends or resistance in small hospitals, as well as proprietary or public hospitals. While discharge
patient characteristics of hospitals participating in voluntary reporting systems for CRE better
approximate US Academic Centers than by all US Hospitals, the participating hospitals tend to
underrepresent patients aged 65 and older and Medicare recipients. Conversely, UHC Participant
Hospitals also over-represent people who were Black/African American. Discharges from UHC
Participant Hospitals were more frequently admitted from other hospitals.
Larger hospitals more frequently participate in studies of organizational and procedural
determinants of infection and control and patient safety programs,23-25 though results presented
here indicate that smaller hospitals actually make up the plurality of all US Hospitals. Larger,
teaching, urban hospitals may have a better quality of care than non-teaching, small, rural
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hospitals.26 For-profit hospitals may have higher mortality rates than public or non-profit
hospitals, and private teaching hospitals have lower mortality rates than private non-teaching
hospitals.27 Larger hospitals and teaching hospitals have higher rates of several antimicrobial
resistant organisms.28 Larger hospitals are also more likely to have staff infection control
specialists and/or laboratory personnel23 who may more easily facilitate surveillance and
reporting internally and externally. Teaching hospitals are also more likely to have an accurate,
disseminated and up-to-date antibiogram,24 typically used empirically to aid in clinical decision
making. For-profit hospitals tend to detect and internally report antimicrobial resistance less
frequently than other hospitals.24 Importantly, evidence suggests that antimicrobial monitoring
and control systems at individual institutions are more frequently implemented as a reaction to
high resistance rates, rather than proactively for prevention.24 As such, interpreting findings from
hospitals participating in voluntary surveillance systems may not adequately capture emerging
trends in resistance.
While increasing age is predictive of CRE infection, gender was not found to be
predictive;3 these and other demographic factors, like race/ethnicity, warrant further
investigation. Typically, independent predictors of CRE infection comprise use of antibiotics,3
including carbapenems,3,10,29 and cephalosporins;4,29 aminoglycosides have previously been
shown as protective.4 Conflicting evidence in the literature exists over the importance of
fluoroquinolones as predictive3,4,10 or protective29. Poor functional status and illness severity
have also been shown to be predictive,3,4 while presence of comorbid conditions was not
associated.4 Stay in the intensive care unit (ICU) has also been predictive of resistant K.
pneumoniae isolation in some studies,3,10 while conflicting evidence is indicated in another.29
While overall the proportions of discharges coded with diagnoses of E. coli or K.
pneumoniae are small (~1%), our study indicated evidence of slight increasing trends in both E.
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coli and K. pneumoniae, coupled with the rise in resistance in K. pneumoniae. If overall burden
is increasing, so is to the opportunity for resistance. Without proper, mandatory reporting and
surveillance measures for these important public health pathogens, it is impossible to monitor
true nationwide prevalence in CRE bacteria. Although current mandatory monitoring of
“traditional” communicable disease by state health departments and the Centers for Disease
Control and Prevention is far from perfect, these systems provide mechanisms of surveillance
and evaluation to drive program planning at all levels of government, and are especially effective
when electronic reporting is used.30,31 For a program mandating reporting of health-care
associated infections to come to fruition, it is imperative that this issue become both an
ideological and fiscal priority.
Proper surveillance of national trends may spur diffusion of promising prevention and
infection control efforts. In a New York hospital where CRE infections are becoming endemic in
the ICU, a comprehensive intervention including cohorting of specific patient groups, routine
rectal surveillance, increased contact isolation and hand hygiene vigilance, and decontamination
of the environment was successful in mitigating an outbreak of CRE.11 Improvements in hand
hygiene, contact precautions and antimicrobial use have also been suggested as prevention
mechanisms for CRE infections.32 These and other mechanisms of prevention will no doubt save
time, finances and lives if CRE and other antimicrobial resistant infections can be prevented.
This study must be considered with certain caveats. First, we were only able to evaluate
antibiogram resistance in a very small sample and each hospital used independent testing
methods (not reported). Resistance in CRE can be measured in one of several ways, including
antibiotic sensitivity analysis,12,33 the Hodge test or modified versions,33 or PCR,33,34
Nevertheless, all methods are imperfect at detecting CRE in vitro,5,33 especially typical and
routine automated methods.5,35. Second, the extent to which we were able to explore hospital and
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patient characteristics was a function of the data elements available. Yet, we were able to provide
a comparison of relatively small reporting systems with a large, nationally representative sample
of patient discharges and hospital characteristics which provides accurate estimates of US
hospitals. The HCUP-NIS is well suited for examining rare diagnoses like E. coli and K.
pneumoniae and allowed us to stratify hospitals by teaching status. Lastly, the number of ICD-9CM codes reported to HCUP varied through time and place. Although we analyzed trend data
according to HCUP standards, it may be that increasing trends were a function of increases in the
number of diagnoses reported rather than true increases in burden.

CONCLUSIONS
Antimicrobial resistance has emerged as a significant public health threat, with the past
quarter-century “ushering in the era of multidrug resistance.”1 Carbapenem resistance is newly
emerging in isolates like Escherichia coli and Klebsiella pneumoniae. Increasing overall burden
of infection due to these isolates only reinforces CRE as an important public health threat and
may warrant the creation of a national, mandatory reporting system for these and other
antimicrobial resistant organisms. Due to the current climate of pharmaceutical production,
preventing the further creation and spread of drug-resistant isolates will not likely stem from new
therapeutics, but rather from control, isolation and antimicrobial stewardship practices across
healthcare settings.32
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Figure 1. The National Burden of Escherichia coli and Klebsiella pneumoniae
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Figure 2. Carbapenem Resistance Trends in Escherichia coli and Klebsiella pneumoniae- select*
UHC Participant Hospitals (n=13)

*There were 13 UHC Participant Hospitals for which data were available for all years; Means reflect all 13 hospitals. Individual
hospitals were not graphed here if data for all years reflected no resistance (0.000).
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Table 1: Patient Level Variables, 2007 Discharges

Sample Size
Weighted Sample Size

Patient Age
Younger than 18 years
18 to 30 years
31 to 50 years
51 to 64 years
65 and older
Patient Sex
Female
Patient Race/Ethnicity
White
Black or African American
Hispanic or Latino
Asian or Pacific Islander
Am. Indian/Alaskan Native
Admission Source
Emergency Room
Another Hospital
Another Facility
Court/Law enforcement
Routine, Birth or Other
Admission Type
Emergency
Urgent Care
Elective
Newborn
Trauma Center
Discharge Status
Died during hospitalization
Primary Payer Source
Medicare
Medicaid
Private Insurance
Self Pay
No Charge for Service
Other

US
Hospitals

US
Academic
Centers

UHC
Participant
Hospitals

8,043,415
39,541,948

3,758,898
18,760,902

1,268,496
N/A

Weighted
Percentage

Weighted
Percentage

Percentage

17.2
12.9
19.7
16.8
33.5

19.2
13.3
21.0
17.4
29.1

16.2
14.4
24.0
21.1
24.3

58.8

57.6

54.4

67.0
15.0
14.2
0.9
2.9

59.6
19.2
16.4
1.1
3.6

60.7
24.7
11.5
2.5
0.5

44.5
3.3
1.3
0.1
50.7

42.8
4.6
1.2
0.1
51.2

39.4
7.9
1.5
0.1
50.4

45.7
17.9
25.0
11.2
0.2

45.6
16.2
26.2
11.6
0.4

41.3
19.3
28.1
9.2
1.3

1.9

1.9

2.2

36.4
19.4
34.8
5.3
0.5
3.5

31.9
21.3
36.4
5.6
0.7
4.0

29.5
22.1
36.7
5.4
0.0
5.5
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Table 2: Hospital Level Variables, 2007

Sample Size
Wt. Sample Size

US
Hospitals

US
Academic
Centers

UHC
Participant
Hospitals

NHSN
Participant
Hospitals

1,044
5,099

191
927

42
N/A

462
N/A

Weighted
Percentage

Weighted
Percentage

Percentage

Percentage

Region
Northeast
12.8
Midwest
29.2
South
39.9
West
18.2
Bed Size *
Small
45.2
Medium
24.3
Large
30.6
Hospital Control *
Public
18.2
Non-profit
18.3
Proprietary
15.5
Private
12.9
Collapsed
35.1
Hospital Teaching Status
Teaching
18.2
Case Mix Index
Mean (SD)
1.18 (0.001)

24.4
27.3
31.0
17.2

26.2
21.4
31.0
21.4

28.0
28.7
43.3

4.8
21.4
73.8

0.0
3.7
0.0
4.2
92.0

0.0
100.0
0.0
0.0
0.0

100.0

100.0

1.25 (0.001)

1.64 (0.18)

* Bed size and hospital control were categorized differently for each data source (see
methods).

32.6
46.9
20.5
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